Arrowstreet Capital
VIR icon

Arrowstreet Capital’s Vir Biotechnology VIR Stock Holding History

Arrowstreet Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-85,800
Closed -$2.95M – 2555
2020
Q3 		$2.95M Buy
+85,800
New +$3.69M ﹤0.01% 1398

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Arrowstreet Capital's VIR Position: Q4 2020 in Review

Arrowstreet Capital sold out of Vir Biotechnology (VIR) in Q4 2020, closing a stake of 85,800 shares — an estimated $2.95M sold.

Arrowstreet Capital first reported a position in VIR in Q3 2020 and held it in 1 quarter. The position peaked at $2.95M in Q3 2020. 143 funds tracked by Wall St. Rank hold VIR as of Q4 2020.

  • Arrowstreet Capital reported no remaining Vir Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 85,800 Vir Biotechnology shares in Q4 2020, an estimated $2.95M.
  • Arrowstreet Capital first reported a position in Vir Biotechnology in Q3 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Vir Biotechnology position peaked at $2.95M in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.